Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024)
Travere Therapeutics (TVTX) posted Current Deferred Revenue of $2.8 million for Q4 2024, down 25.9% on a QoQ basis from $3.8 million in Q3 2024, and down 68.48% year-over-year from $8.9 million in Q1 2024.
Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024) Analysis & Trends
Travere Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $2.8 million for Q4 2024.
- Quarterly Current Deferred Revenue fell 68.48% year-over-year to $2.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.8 million (down 68.48% YoY) and the FY2024 annual result came in at $2.8 million, down 68.48% from the prior year.
- Current Deferred Revenue was $2.8 million for Q4 2024 at Travere Therapeutics, down from $3.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $43.0 million in Q3 2021 and bottomed at $2.8 million in Q4 2024.
- A 4-year average of $14.2 million and a median of $10.6 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue tumbled 73.53% — and 2023, when it dropped 18.07%.
- Travere Therapeutics' Current Deferred Revenue stood at $36.6 million in 2021, then tumbled by 37.49% to $22.9 million in 2022, then slumped by 61.01% to $8.9 million in 2023, then sank by 68.48% to $2.8 million in 2024.
- Business Quant data shows TVTX's Current Deferred Revenue at $2.8 million in Q4 2024, $3.8 million in Q3 2024, and $5.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 8.96 Mn |
| Jun 30, 2023 | 10.24 Mn |
| Mar 31, 2023 | 10.98 Mn |
| Dec 31, 2022 | 22.91 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 12.50 Mn |
| Mar 31, 2022 | 14.23 Mn |
| Dec 31, 2021 | 36.65 Mn |
| Sep 30, 2021 | 43.00 Mn |